Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month High - Should You Buy?

Key Points

• Shares of Ascentage Pharma Group International reached a new 52-week high of $45.00 during trading, with a notable increase of 4.7% from the previous close.
• The company has attracted interest from institutional investors, with multiple hedge funds acquiring new positions in the stock, totaling significant investments from firms such as Monashee Investment Management and HSBC Holdings.
• Ascentage Pharma is a clinical-stage biotechnology company focused on developing therapies for cancer, hepatitis B, and age-related diseases, based in Suzhou, China.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - ) hit a new 52-week high during trading on Friday . The company traded as high as $45.00 and last traded at $45.00, with a volume of 2063 shares traded. The stock had previously closed at $42.45.

Ascentage Pharma Group International Trading Up 4.7%

The business has a 50-day simple moving average of $38.17. The company has a debt-to-equity ratio of 3.24, a quick ratio of 1.26 and a current ratio of 1.26.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors and hedge funds have recently modified their holdings of AAPG. Monashee Investment Management LLC acquired a new position in shares of Ascentage Pharma Group International in the first quarter valued at $3,511,000. Tema Etfs LLC bought a new position in Ascentage Pharma Group International during the second quarter worth about $610,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, Chevy Chase Trust Holdings LLC bought a new position in Ascentage Pharma Group International during the second quarter worth about $227,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.